Basiliximab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Basiliximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (mouse/human)
TargetCD25
Clinical data
Trade namesSimulect
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: D
ATC code
Pharmacokinetic data
Elimination half-life7.2 days
Identifiers
CAS Number
  • 179045-86-4 ☒N
DrugBank
ChemSpider
  • none
UNII
ChEMBL
Chemical and physical data
FormulaC6378H9844N1698O1997S48
Molar mass143801.68 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Basiliximab (trade name Simulect) is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants.

Uses[edit]

Basiliximab is an immunosuppressant agent used to prevent immediate transplant rejection in people who are receiving kidney transplants, in combination with other agents.[1] It has been reported that some cases of lichen planus have been successfully treated with basiliximab as an alternative therapy to cyclosporin. No short-term side effects have been reported.[2]

Mechanism of action[edit]

Basiliximab competes with IL-2 to bind to the alpha chain subunit of the IL2 receptor on the surface of the activated T lymphocytes and thus prevents the receptor from signaling. This prevents T cells from replicating and also from activating B cells, which are responsible for the production of antibodies, which would bind to the transplanted organ and stimulate an immune response against the transplant.[3][4]

Chemistry[edit]

It is a chimeric CD25 monoclonal antibody of the IgG1 isotype.[3][4]

History[edit]

It is a Novartis product and was approved by the Food and Drug Administration (FDA) in 1998.[5]

See also[edit]

References and notes[edit]

  1. ^ MedlinePlus. Last Revised - June 15, 2012 Basiliximab Injection
  2. ^ Katsambas AD, Lotti TM (2003). European handbook of dermatological treatments (2nd ed.). p. 291. ISBN 3-540-00878-0.
  3. ^ a b Hardinger KL, Brennan DC, Klein CL (July 2013). "Selection of induction therapy in kidney transplantation". Transplant International. 26 (7): 662–72. doi:10.1111/tri.12043. PMID 23279211. S2CID 3296555.
  4. ^ a b Basiliximab label
  5. ^ Waldmann TA (March 2003). "Immunotherapy: past, present and future". Nature Medicine. 9 (3): 269–77. doi:10.1038/nm0303-269. PMID 12612576. S2CID 9745527.